Composition: Cefoperazone + Sulbactam
Strengths: 1.5g
Dosage From: Powder for reconstitution for injection.
Pharmacodynamics: The antibacterial component of Sulbactam/Cefoperazone is cefoperazone, a third-generation Cephalosporin, which acts against sensitive organisms during the stage of active multiplication by inhibiting the biosynthesis of cell wall mucopeptide. Sulbactam does not possess any useful antibacterial activity, except against Neisseriaceae and Acinetobacter. As sulbactam also binds with some penicillin-binding proteins, sensitive strains are also often rendered more susceptible to Sulbactam/Cefoperazone than to Cefoperazone alone. The combination of Sulbactam and Cefoperazone is active against all organism’s sensitive to Cefoperazone. In addition, it demonstrates synergistic activity (up to 4-fold reduction in the minimum inhibitory concentrations for the combination versus those for each component) in a variety of organisms.
Indications:
Dosage:Dosage should be administered every 12 hours in equally divided doses. In severe or refractory infections, the daily dosage of sulbactam/cefoperazone may be increased up to 8g of the 1:1 ratio (i.e., 4g of cefoperazone activity) or 12g of the 1:2 ratios (i.e., 8g of cefoperazone activity). Patients receiving the 1:1 ratio may require additional cefoperazone administered separately. Doses should be administered every 12 hours in equally divided doses. The recommended maximum daily dosage of sulbactam is 4g.
Contraindications:It is contraindicated in patients with a known allergy, sulbactam, cefoperazone, or any of the cephalosporins.
Warnings and Precautions:Serious and occasionally fatal hypersensitivity (anaphylactic) reactions have been reported in patients receiving beta-lactam or cephalosporin therapy. These reactions are more apt to occur in individuals with a history of hypersensitivity reactions to multiple allergens. If an allergic reaction occurs, the drug should be discontinued and the appropriate therapy instituted. As with other antibiotics, overgrowth of non-susceptible organisms may occur during the prolonged use of Sulbactam/Cefoperazone. It has been extensively studied in premature infants or neonates. Therefore, in treating premature infants and neonates, the potential benefits and possible risks involved should be considered before instituting therapy.